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Abstract
The carbohydrate-deficient glycoprotein syndromes (CDGS) are a group of autosomal recessive multisystemic diseases
characterized by defective glycosylation of N-glycans. This review describes recent findings on two patients with CDGS type
II. In contrast to CDGS type I, the type II patients show a more severe psychomotor retardation, no peripheral neuropathy
and a normal cerebellum. The CDGS type II serum transferrin isoelectric focusing pattern shows a large amount (95%)
of disialotransferrin in which each of the two glycosylation sites is occupied by a truncated monosialo-monoantennary
N-glycan. Fine structure analysis of this glycan suggested a defect in the Golgi enzyme UDP-GlcNAc:K-6-D-mannoside
L-1,2-N-acetylglucosaminyltransferase II (GnT II; EC 2.4.1.143) which catalyzes an essential step in the biosynthetic
pathway leading from hybrid to complex N-glycans. GnT II activity is reduced by over 98% in fibroblast and mononuclear
cell extracts from the CDGS type II patients. Direct sequencing of the GnT II coding region from the two patients identified
two point mutations in the catalytic domain of GnT II, S290F (TCC to TTC) and H262R (CAC to CGC). Either of these
mutations inactivates the enzyme and probably also causes reduced expression. The CDG syndromes and other congenital
defects in glycan synthesis as well as studies of null mutations in the mouse provide strong evidence that the glycan moieties
of glycoproteins play essential roles in the normal development and physiology of mammals and probably of all multi-
cellular organisms. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
At least 0.5^1% of the transcribed human genome
is devoted to the production of proteins involved in
the synthesis, degradation and function of glycocon-
jugates [1]. It is therefore not surprising that there
are many congenital diseases with defects in these
pathways. Table 1 lists eight autosomal recessive dis-
eases in which there is a defect in the synthesis of
Asn-linked glycans (N-glycans) proving that these
structures are essential for normal human develop-
ment. Some of these diseases are discussed in other
chapters of this volume. This chapter will focus on
carbohydrate-de¢cient glycoprotein syndrome type II
(CDGS II).
The carbohydrate-de¢cient glycoprotein syn-
dromes are a group of congenital multi-systemic dis-
eases characterized by defective glycosylation of N-
glycans. The discovery of this disease was based on
the observation by Jaeken et al. [2] of decreased se-
rum thyroxine-binding globulin and increased aryl-
sulfatase A activity in two patients with familial psy-
chomotor retardation. In 1984, Jaeken et al. [3]
reported sialic acid de¢ciency in serum and cerebro-
spinal £uid transferrin from identical twin-sisters
with demyelinating disease and thereby ¢rst showed
that this new syndrome was due to defective protein
glycosylation. There were about 280 patients with
this disease world-wide as of October, 1998 [4]. Until
recently, four variants of CDGS were recognized
(called types I^IV) based primarily on the quantita-
tive analysis of serum transferrin glycoforms either
by isoelectric focusing or chromatofocusing. Varia-
tions in the pattern of transferrin glycoforms re£ect
di¡erences in negative charge due to abnormal sialyl-
ation of protein-bound N-glycans (described in more
detail below). Within the last 3 years, at least three
distinct variants of CDGS associated with a type I
transferrin pattern have been described (designated
types Ia, Ib and Ic). The enzymatic and genetic de-
fects in these variants have been determined and it is
clear that there are other CDGS type I patients with
as yet undetermined metabolic defects. CDGS types
III [5] and IV [6] cases are very rare and nothing is
known about the biochemical defects in these pa-
tients.
2. Clinical presentations of CDGS
CDGS I occurs world-wide and a¡ects both sexes
equally [4,7]. The patients show moderate to severe
neurological disease (cerebellar ataxia and marked
psychomotor retardation), a characteristic dysmor-
phy and variable involvement of other organs. Feed-
ing problems, vomiting and diarrhea may occur re-
sulting in severe developmental delay and failure to
thrive [8,9]. Infants may show a distinctive lipodys-
trophy (peculiar distribution of subcutaneous fat),
nipple retraction and hypogonadism. After infancy,
retinitis pigmentosa [10,11], joint contractures, skel-
etal deformities [12], stroke-like episodes, epilepsy
and peripheral neuropathy may develop. About
20% of the patients die within the ¢rst year. Lan-
guage and motor development are severely delayed
and walking without support is rarely achieved. The
IQ ranges from 40 to 60 and the children usually
have an extroverted and cheerful disposition. Com-
puterized tomography (CT), nuclear magnetic reso-
nance imaging (MRI) and postmortem studies of the
brain of CDGS I patients often show olivopontocer-
ebellar atrophy (OPCA) and a small brain stem [13^
20].
Two CDGS patients, designated as CDGS II, have
been described who di¡er from the classic picture of
CDGS I described above, an Iranian girl (patient A)
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[21] and a Belgian boy (patient B) [22,23]. In contrast
to CDGS I, both CDGS II patients had a more
severe psychomotor retardation, no peripheral neu-
ropathy and a normal cerebellum on MRI. Both pa-
tients had a similar dysmorphy particulary of the
face (coarse features, low-set ears), widely spaced
nipples, a ventricular septal defect, a striking stereo-
typic behavior (tongue thrusting, hand washing and
other movements), generalized hypotonia and limb
weakness, and normal deep tendon re£exes. Patient
A was lost from follow-up after the age of 3 years.
Patient B’s speech was limited to a few monotonous
sounds at 10 years. He su¡ered from frequent infec-
tions in infancy and epilepsy developed at 6 years.
The diagnosis of CDGS was not made until patient
B was 9.5 years old when an investigation of bleeding
gums revealed a typical CDGS coagulopathy. Radio-
logical examination showed osteopenia and other
skeletal abnormalities. MRI revealed absence of cer-
ebellar atrophy, but showed delayed myelination and
global cortical atrophy.
3. The analysis of serum transferrin glycoforms in
CDGS
The basic defect in CDGS is defective N-glycosyl-
ation of glycoproteins throughout the body, which
explains the severe multi-systemic nature of the dis-
ease. Diagnosis can be made by examination of the
complex N-glycans on any glycoprotein. The most
convenient source of glycoproteins is serum and the
protein usually used is transferrin because of the rel-
ative simplicity of its glycosylation. Serum transferrin
has only two asparagine N-glycosylation sites per
molecule, both of which are normally occupied by
complex N-glycans, primarily of the disialo-bianten-
nary N-acetyllactosamine type with smaller amounts
of monosialo-biantennary, disialo-triantennary, tri-
sialo-triantennary and tetrasialo-tetraantennary N-
glycans (Fig. 1) [13,24^30]. Normal serum transferrin
therefore exists as a series of glycoforms containing
two to seven sialic acid residues per mole of protein
(designated S2 to S7, Fig. 1). Chromatofocusing, iso-
electric focusing, capillary zone electrophoresis and
anion exchange chromatography have been used to
analyze human serum transferrin glycoforms [3,31^
35]. The normal glycoform concentrations are: S2,
1^7%; S3, 4^17%; S4, 46^73%; S5, 10^30%; S6, 0^
9%; S7, traces. The corresponding values for CDGS
sera showing a type 1 pattern [3,20,31,33,36^38] are:
S2, 14^37%; S3, 6^19%; S4, 18^57%; S5, 5^17%; S6,
0^6%. In addition, CDGS I sera show appreciable
amounts of S0 (2^29%), a glycoform not usually de-
tected in normal sera. In other words, CDGS I sera
show dramatic reductions in S4 and S5 and dramatic
increases in S0 and S2 (Fig. 1). Data from many
laboratories indicate an ‘all-or-none’ situation in
which each glycosylation site on transferrin is either
occupied by a normal N-glycan or is not occupied
suggesting that the addition of oligosaccharide to
Asn is the defective step (Fig. 1) [13,35,39^42].
The CDGS II serum transferrin isoelectric focus-
ing pattern di¡ers markedly from that in CDGS I
(Fig. 1) in that there are no or minimal amounts of
asialo-, tetrasialo-, pentasialo- and hexasialo-trans-
ferrrins, low amounts of monosialo-transferrin, a
moderate amount (about 4%) of trisialo-transferrin
and a large amount (95%) of disialo-transferrin
[23,28,29].
Electrospray-mass spectrometry analysis of both
normal and CDGS II puri¢ed serum transferrin
showed seven glycoform peaks (I^VII) with molecu-
lar masses ranging from 79 265 to 80 369 Da for nor-
mal transferrin and 77 958 to 79 130 Da for CDGS II
transferrin [28]. On the basis of a polypeptide chain
molecular mass of 75 143 Da, it was calculated that
the major transferrin species III (79 557 and 78 247
Da for normal and CDGS II transferrin, respec-
tively) are, respectively, tetrasialo-transferrin (S4) in
which each glycosylation site is occupied by a disialo-
biantennary N-acetyllactosamine type N-glycan and
disialo-transferrin (S2) in which each glycosylation
site is occupied by a truncated monosialo-monoan-
tennary N-glycan (Fig. 1). The minor peaks I, V and
VI for normal transferrin represent respectively S3
(disialo-biantennary and monosialo-biantennary N-
glycans), S4 (disialo-biantennary and disialo-trian-
tennary) and S5 (disialo-biantennary and trisialo-tri-
antennary). The corresponding peaks for CDGS II
transferrin represent respectively S1 (truncated
monosialo-monoantennary and asialo-monoanten-
nary N-glycans), S2 (truncated monosialo-mono-
antennary and monosialo-biantennary) and S3
(truncated monosialo-monoantennary and disialo-
biantennary) (Fig. 1). Transferrin species I and V
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correspond to the desialylated forms of species III
and VI, respectively. Peaks II and IV are probably
sulfated derivatives and peak VII has not been iden-
ti¢ed.
CDGS II serum transferrin was isolated by immu-
noa⁄nity chromatography and separated into minor
and major fractions by fast protein liquid chroma-
tography. The structure of the glycans released from
the major fraction by hydrazinolysis was established
by application of methanolysis and high resolution
proton NMR spectroscopy [28]. The major N-glycan
is the truncated monosialo-monoantennary N-glycan
ManK1^6[NeuNAcK2^6GalL1^4GlcNAcL1^2Man-
K1^3]Man-R where R is -L1-4GlcNAcL1-4GlcNAc-
Asn-X. The presence of truncated N-glycans clearly
di¡erentiates the CDGS II transferrin glycoform pat-
tern from the ‘all-or-none’ model described above for
CDGS I (Fig. 1). The parents of the CDGS II pa-
tients showed a normal pattern.
The large amount of normal transferrin glycoform
S4 in CDGS I serum indicates that this mutation is
quite leaky. In contrast, the mass spectrometry data
[28] indicate that there is little, if any, normal S4 in
CDGS II serum. The small amount of S4 seen on
isoelectric focusing is probably a truncated derivative
of S6 (Fig. 1). Thus the mutation in CDGS II ap-
pears to be stringent.
4. Clinical biochemistry
Since there is defective glycosylation of all N-gly-
cosylated glycoproteins, it is not surprising that
many glycoproteins in CDGS I serum (transporters,
hormones, complement factors, clotting factors and
inhibitors, lysosomal enzymes and others) [2,3,20,36^
38,43^55], cerebrospinal £uid [3,56], leukocytes [50],
¢broblasts [57,58] and liver [37] show abnormal het-
Fig. 1. Structures of S0^S7 transferrin glycoforms. Serum transferrin has two asparagine N-glycosylation sites per molecule. In normal
transferrin (structures in upper section of ¢gure), both sites are occupied by complex N-glycans, primarily of the disialo-biantennary
N-acetyllactosamine type with smaller amounts of monosialo-biantennary, disialo-triantennary, trisialo-triantennary and tetrasialo-tet-
raantennary N-glycans. Normal serum transferrin exists as a series of glycoforms containing two to seven sialic acid residues per mol
of protein (designated S2^S7). Box I shows the abnormal S0^S3 underglycosylated structures found in CDGS I (the ‘all-or-none’
structures, see text). Box II shows the abnormal S1^S3 underglycosylated structures found in CDGS II. The major glycoform in nor-
mal transferrin is the S4 structure marked with an X. The major glycoforms in CDGS I are: (1) the normal S4 structure marked with
an X; (2) the two S2 structures marked with an X in Box I; and (3) the S0 structure in Box I. The major glycoform in CDGS II is
the abnormal S2 structure marked with an X in Box II. The insert in the lower right of the ¢gure shows a diagram of the isoelectric
focusing pattern of the major serum transferrins in normal controls (C), CDGS I (I) and CDGS II (II). (References to serum transfer-
rin analysis : [3,13,24^41].) a, GlcNAc; F, Man; b, Gal; E, sialic acid.
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erogeneity due to incomplete glycosylation. Not only
is there hypoglycosylation of serum glycoproteins but
the levels of various serum glycoproteins may be de-
creased or increased probably secondary to damage
to the liver and other organs or to missorting, defec-
tive reuptake and/or reduced stability of underglyco-
sylated glycoproteins, e.g. glycoprotein transport
along the secretory pathway in CDGS I skin ¢bro-
blasts may be delayed and dilation of the rough en-
doplasmic reticulum has been observed indicating re-
tention of selected glycoproteins [59].
Although many of the abnormal serum glycopro-
tein levels are similar for both CDGS I and II, there
are some signi¢cant di¡erences, e.g. CDGS II pa-
tients show absence of proteinuria, a de¢ciency of
clotting factors IX and XII, decreased L-glucuroni-
dase, and normal serum glutamic pyruvic transami-
nase activity, albumin, cholesterol and arylsulfatase
A. As occurs in CDGS I, patient B showed decreased
levels of many serum glycoproteins (thyroxine-bind-
ing globulin, clotting factor XI, antithrombin III,
proteins C and S, heparin cofactor II, L-galactosi-
dase, K1-antitrypsin, apolipoprotein B, haptoglobin).
Serum IgM and cerebrospinal £uid protein were ele-
vated.
Human L-trace protein is a major intrathecally
synthesized polypeptide constituent of human cere-
brospinal £uid (CSF). The L-trace protein from the
two CDGS II patients showed a single di-N-glycosy-
lated protein band with a signi¢cantly lower molec-
ular weight than the di-N-glycosylated polypeptide
from control CSF [56]. The major oligosaccharide
structures of the glycoprotein from CDGS II patients
were asialo-monoantennary and monosialo-monoan-
tennary lactosamine-type chains with a core fucose
and a bisecting GlcNAc.
5. Complex N-glycan synthesis within the Golgi
apparatus
The CDGS type I serum transferrin glycoform
pattern implies a leaky mutation in either oligosac-
charyltransferase (OT, Fig. 2) or in one of the steps
Fig. 2. Metabolic pathway from glucose and mannose to dolichol pyrophosphate oligosaccharide. Enzymes: HK, hexokinase; GK,
glucokinase; PGI, phosphoglucoisomerase; PGM, phosphoglucomutase; PMI, phosphomannoisomerase; PMM, phosphomannomu-
tase; Glc-T, glucosyltransferase; Man-T, mannosyltransferase; oligo-T, oligosaccharyltransferase. Asterisks on PMM, PMI and Glc-T
denote enzyme defects in CDGS Types Ia, Ib and Ic, respectively (Table 1). Intermediates : G-6-P, glucose-6-phosphate; G-1-P,
glucose-1-phosphate; F-6-P, fructose-6-phosphate; M-6-P, mannose-6-phosphate; M-1-P, mannose-1-phosphate; UDPG, UDP-glu-
cose; Dol-P-Glc, dolichol phosphate glucose; Dol-P-Man, dolichol phosphate mannose; dolichol-PP-(GlcNAc)2, dolichol pyrophos-
phate N-acetylchitobiose; dolichol-PP-oligosaccharide, dolichol pyrophosphate (Glc)3(Man)9(GlcNAc)2. Dolichol pyrophosphate
(Glc)3(Man)9(GlcNAc)2 is assembled by the addition of Man from both GDP-Man and Dol-P-Man and Glc from Dol-P-Glc to doli-
chol-PP-(GlcNAc)2.
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in the synthetic pathway to dolichol pyrophosphate
oligosaccharide (Fig. 2). These mutations occur in
the rough endoplasmic reticulum or cytoplasm
(Figs. 2 and 3). Leukocyte adhesion de¢ciency type
II and galactosemia (Table 1) are also cytoplasmic
diseases. However, inclusion cell disease, CDGS II
and HEMPAS (Table 1) are diseases in which there
is a defect in the processing of N-glycans within the
Golgi apparatus (Fig. 3). The ¢rst committed step in
the conversion of oligomannose to complex and hy-
brid N-glycans is catalyzed by UDP-GlcNAc:K-3-D-
mannoside L-1,2-N-acetylglucosaminyltransferase I
(GnT I; EC 2.4.1.101, Fig. 3). GnT I adds a GlcNAc
residue to the ManK1^3ManL1-R arm of ManK1^
6(ManK1^3)ManK1^6[ManK1^3]ManL1-R to form
ManK1^6(ManK1^3)ManK1^6[GlcNAcL1^2ManK1^
3]ManL1-R where R is -4GlcNAcL1-4GlcNAc-Asn-
X. GnT I action is an essential pre-requisite for the
action of several enzymes leading to complex N-gly-
cans, K-3/6-mannosidase II, GlcNAc-transferases II,
III and IV and core K-1,6-fucosyltransferase [60,61].
The human GnT I gene (MGAT1) has been mapped
to chromosome 5q35 [62^64].
Processing of the product of GnT I, ManK1^
6(ManK1^3)ManK1^6[GlcNAcL1^2ManK1^3]Man-
L1-R, by K-3/6-mannosidase II (MII, EC 3.2.1.114)
to form ManK1^6[GlcNAcL1^2ManK1^3]ManL1-R
is the ¢rst committed step in the conversion of hybrid
to complex N-glycans (Fig. 3) [61,65^68]. GnT I and
MII are type II integral membrane glycoproteins fac-
ing the lumen of the Golgi membrane [69]. At least
some patients with HEMPAS have a de¢ciency of
MII [70,71].
UDP-GlcNAc:K-6-D-mannoside L-1,2-N-acetylglu-
cosaminyltransferase II (GnT II; EC 2.4.1.143) cata-
lyzes incorporation of a GlcNAc residue in L1,2 link-
age to the ManK1^6 arm of ManK1^6[GlcNAcL1^
2ManK1^3]ManL1-R to form GlcNAcL1^2ManK1^
6[GlcNAcL1^2ManK1^3]ManL1-R and is therefore
an essential step in the biosynthetic pathway leading
from hybrid to complex N-glycans (Fig. 3). GnT II is
a typical type II transmembrane protein [64,72] and
has been mapped to human chromosome 14q21.
6. The genetic defect in CDGS II
The truncated N-glycans found in CDGS II serum
transferrin (Fig. 1) indicate that CDGS II patients
have a defect in GnT II. Indeed, GnT II activity
was reduced by over 98% in ¢broblast extracts
from the two unrelated CDGS II patients [23] and
there was no detectable GnT II activity in mononu-
clear cell extracts from patient B (Fig. 4) [73].
Table 1
Autosomal recessive disorders with defective N-glycan synthesis
Name of disease Type of disease Enzyme defect Reference
Inclusion cell disease
(I-cell disease or
(mucolipidosis II)
Lysosomal glycoprotein storage
disease with severe developmental
abnormalities
Phospho-N-acetyl glucosaminyl-transferase required
for synthesis of Man-6-phosphate targeting signal
[112^116]
Leukocyte adhesion
de¢ciency type II
(LAD II)
Immunode¢ciency and severe
developmental abnormalities
Defective synthesis of GDP-fucose [117^120]
Carbohydrate-de¢cient glycoprotein syndromes (CDGS)
CDGS type Ia Severe developmental abnormalities Phosphomanno-mutase 2 defect (85% of Type 1) See text and
[4,20,121,122]
CDGS type 1b Gastrointestinal^hepatic problems Phosphomannose isomerase defect [123^125]
CDGS type 1c
(also called type V)
Developmental abnormalities Glucosyltransferase defect [86,126]
CDGS type II Severe developmental abnormalities GlcNAc-transferase II de¢ciency See text and
[21^23,73,74]
HEMPAS (congenital
dyserythropoietic
anemia type II)
Relatively mild disease with mild
anemia and hemosiderosis
K-Mannosidase II de¢ciency. Other factors? See text and
[127^129]
Galactosemia Failure to thrive, liver disease, mental
retardation, cataracts
(i) Galactokinase; (ii) galactose-1-phosphate
uridyltransferase
[79^81]
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Direct sequencing in both directions of the entire
GnT II coding region from the two patients identi-
¢ed two point mutations in the catalytic domain of
GnT II, S290F (TCC to TTC) in patient A and
H262R (CAC to CGC) in patient B [74]. Both muta-
tions occur in the C-terminal catalytic domain [61,75]
at locations which are conserved between rat and
human GnT II [64]. Both patients are homozygous
for their respective mutations and have therefore in-
herited the same allele from each parent. The father,
mother and brother of patient B show one normal
allele and one allele with the same mutation as pa-
tient B.
The CDGS II mutations were introduced into the
normal MGAT2 gene followed by expression in the
baculovirus/Sf9 system [74]. No enzyme activity was
detected in cells transfected by either of the two mu-
tant genes (less than 1% of the control value). West-
ern blot analysis showed that both mutant proteins
were expressed at about 8% of the level of normal
GnT II expression indicating that the mutations ei-
ther interfere with transcription^translation or lower
the stability of the protein in the baculovirus/Sf9 sys-
tem. Northern blot analysis showed normal tran-
scription of the GnT II gene in CDGS II ¢broblasts.
Fig. 4. GnT II analyses on mononuclear cell extracts (from pa-
tient B, his blood relatives and controls) expressed as a ratio of
activity of GnT II relative to activity of GnT I [29,73]. The as-
signment of genotype is based on restriction endonuclease anal-
ysis of DNA for the presence of the GnT II gene mutation
[74]. Symbols: encircled solid square, CDGS II patient B; solid
squares, related heterozygotes; solid circles, blood relatives of
patient B who are homozygous normals; open squares, controls
unrelated to patient B. Mononuclear cell extracts from all 13
heterozygotes have GnT II levels which are 32^67% lower than
normal levels.
Fig. 3. Pathway from dolichol pyrophosphate oligosaccharide to complex N-glycans. Oligosaccharyltransferase (OT) transfers
(Glc)3(Man)9(GlcNAc)2 from dolichol pyrophosphate oligosaccharide to an Asn residue in a nascent peptide chain in the rough endo-
plasmic reticulum. The glycosylated peptide is released from the ribosome into the lumen and undergoes processing by K-glucosidases
and K-mannosidases as it moves through the lumen of the endoplasmic reticulum and Golgi apparatus. In the medial Golgi compart-
ment, the successive actions of N-acetylglucosaminyltransferase I (GnT I), K-mannosidase II (MII) and N-acetylglucosaminyltransfer-
ase II (GnT II) convert the oligomannose N-glycan (Man)5(GlcNAc)2-peptide to the biantennary complex N-glycan
(GlcNAc)2(Man)3(GlcNAc)2-peptide. The defects in CDGS Types Ia, Ib and Ic (Table 1, Fig. 2) all result in defective synthesis of do-
lichol pyrophosphate oligosaccharide which therefore results in defective OT action. HEMPAS and CDGS II are due, respectively, to
defects in the Golgi enzymes MII (at least in some cases) and GnT II.
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It remains to be established whether there is a defect
of either translation or protein stability in human
cells. The data suggest that the mutations reduce
protein expression and also inactivate GnT II en-
zyme activity. It is of interest that although the mu-
tations in the two patients are di¡erent, they cause
the identical phenotype.
Restriction endonuclease analysis of DNA from 23
blood relatives of one of these patients showed that
13 donors were heterozygotes; the other relatives and
21 unrelated donors were normal homozygotes [74].
All heterozygotes showed a signi¢cant reduction (33^
68%) in mononuclear cell GnT II activity (Fig. 4).
Analysis of patient B’s family proves that CDGS II
is a recessive autosomal disease located at chromo-
some 14q21.
7. The diagnosis of CDGS II
The characteristic serum transferrin glycoform pat-
tern (Fig. 1) is the most commonly used diagnostic
criterion for CDGS. Iron saturation is required for
accurate analysis of transferrin glycoforms and only
serum or heparin plasma should be used [76,77]. It is
essential to perform a detailed glycoform analysis for
the diagnosis of the various CDGS types since car-
bohydrate-de¢cient serum transferrin also occurs in
other conditions, such as chronic alcohol intake [78],
galactosemia [79^81], untreated fructosemia [82,83]
and hepatic disease [78].
Once a diagnosis of CDGS II has been con¢rmed
by demonstration of the typical transferrin (or other
glycoprotein) glycoform pattern (Fig. 1), GnT II as-
says should be carried out on fresh monocytes (Fig.
4) or on cultured ¢broblast or lymphoblast extracts.
Diagnosis can also be made by GnT II assays on
parental monocytes (Fig. 4). The diagnosis can be
con¢rmed by molecular mass determination of serum
transferrin with electrospray-mass spectrometry
[28,39^41]. The diagnosis should be completed by
mutational analysis [74], although this may not be
a simple matter due to the strong possibility that
unrelated cases of CDGS II will have di¡erent muta-
tions.
The serum glycoprotein glycoform patterns are
normal in the CDGS I fetus, and probably also in
the CDGS II fetus, and therefore pre-natal diagnosis
is not possible by this method [84]. Abnormal glyco-
form patterns in CDGS I appear in the second to
third weeks of post-natal life. It is now possible to
carry out pre-natal testing of CDGS II by GnT II
assays and mutation analysis of the GnT II gene
using chorionic villus samples, cultured chorionic vil-
lus cells or cultured amniocytes [85]. A thorough
molecular work-up of both the patient and family
should probably be carried out on all future sus-
pected cases of CDGS.
Screening for CDGS transferrin glycoforms by iso-
electric focusing or an equivalent technique is recom-
mended for patients not only with psychomotor re-
tardation and hypotonia, but also in unexplained
feeding problems with failure to thrive, liver ¢brosis,
decreased coagulation factor XI and antithrombin
III, and intestinal disease, even in the absence of
severe neurological disease. Although very useful,
the analysis of glycans on serum transferrin glyco-
forms can be misleading since hypoglycosylation of
glycosyltransferases and glycosidases may a¡ect their
activity or intracellular localization, thereby produc-
ing secondary alterations in carbohydrate structure
[86].
8. The function of complex N-glycans in development
The synthesis of complex N-glycans is divided into
three distinct stages (Figs. 2 and 3). The ¢rst stage
occurs primarily in the cytoplasm and rough endo-
plasmic reticulum and involves the synthesis of doli-
chol pyrophosphate Glc3Man9GlcNAc2. The second
stage begins with the transfer of Glc3Man9GlcNAc2
oligosaccharide to an Asn residue and involves proc-
essing to Man5GlcNAc2-Asn-X, the substrate for
GnT I. The third stage completes complex N-glycan
synthesis and occurs primarily in the Golgi appara-
tus.
Complex N-glycans are absent from bacteria [87]
and yeast [88] and are present in very small amounts,
if at all, in protozoa (Trypanosoma cruzi [89], Leish-
mania [90] and Plasmodium [91]) and Dictyostelium
discoideum [92]. However, all of the above organisms
except bacteria are capable of making N-glycans of
the oligomannose type and therefore express the en-
zymes of stage one and at least some of the enzymes
of stage two of N-glycan synthesis.
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Complex N-glycans are present in most of the mul-
ti-cellular invertebrate and vertebrate animals that
have been analyzed, i.e., nematodes [93^95], schisto-
somes [96^98], molluscs [99,100], insects [101], ¢sh
[102], birds [103^106] and mammals. These species
therefore express all three stages of N-glycan synthe-
sis.
Tunicamycin is an antibiotic which inhibits the
¢rst enzyme in the synthesis of dolichol pyrophos-
phate Glc3Man9GlcNAc2 and therefore prevents all
N-glycosylation of proteins [107]. Tunicamycin inhib-
its replication in yeast, fungi, protozoa, enveloped
viruses and mammalian cell lines in culture [107].
Yeast temperature-sensitive mutants with defects in
the steps leading to the Man5GlcNAc2-Asn-X core
are not viable at the restrictive temperature, whereas
mutations in later stages of oligosaccharide assembly
are not lethal [88,108]. Children with CDGS types 1a
and 1c with defects in the ¢rst stage of N-glycan
synthesis show moderate to severe psychomotor re-
tardation and other multi-systemic abnormalities.
Therefore stage one and at least part of stage two
of N-glycan synthesis are highly conserved in evolu-
tion and are essential for organisms from yeast to
man. It is not known why oligomannose N-glycans
are essential for the viability of uni-cellular organ-
isms.
The third stage of N-glycan synthesis and complex
N-glycans probably appeared in evolution just prior
to the development of multi-cellular organisms sug-
gesting that complex N-glycans are required for the
cell^cell interaction process and normal development
of multi-cellular animals. In support of this concept,
it has been shown that somatic Chinese hamster ova-
ry cell mutants lacking the GnT I gene show essen-
tially normal growth in tissue culture, whereas mouse
embryos with a null mutation in this gene do not
survive beyond 10.5 days post-fertilization and
show severe developmental abnormalities particu-
larly of the brain [109,110]. Mice with a homozygous
null mutation in the gene encoding GnT II survive to
term, but are born stunted with various congenital
abnormalities and die shortly after birth (J. Marth,
personal communication and [111]). Children with
CDGS type II have a defective GnT II gene and
show severe psychomotor retardation and other mul-
ti-systemic abnormalities. These studies indicate that
although complex N-glycans are not essential for the
growth of cells in tissue culture, they play critical
roles in cell^cell interactions and the morphogenesis
of multi-cellular organisms.
In conclusion, the CDG syndromes and other con-
genital defects in glycan synthesis provide strong evi-
dence that the glycan moieties of glycoproteins play
essential roles in the normal development and phys-
iology of mammals and probably of all multi-cellular
organisms.
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